\u8f89\u745e\u5236\u836fPfizer\uff08NYSE:PFE\uff09<\/a>\u7684\u80a1\u4ef7\u6700\u8fd1\u51fa\u73b0\u4e0b\u8dcc\uff0c\u6b64\u524d\u8be5\u516c\u53f8\u5ba3\u5e03\u7ec8\u6b62\u4e00\u6b3e\u6f5c\u5728\u7684\u7cd6\u5c3f\u75c5\u548c\u51cf\u91cd\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002\u5177\u4f53\u6765\u8bf4\uff0c\u6709\u4e9b\u60a3\u8005\u5728\u63a5\u53d7\u80f0\u9ad8\u8840\u7cd6\u7d20\u6837\u80bd-1\u53d7\u4f53\u6fc0\u52a8\u5242\uff08GLP-1-RA\uff09\u5019\u9009\u4ea7\u54c1lotiglipron\u6cbb\u7597\u540e\u809d\u9176\u6c34\u5e73\u51fa\u73b0\u4e0a\u5347\u3002\u4f46\u4e0e\u6b64\u540c\u65f6\uff0c\u53e6\u4e00\u6b3e\u6cbb\u7597\u80a5\u80d6\u75c7\u548c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u7684GLP-1-RA\u5019\u9009\u4ea7\u54c1danuglipron\u7684\u8bd5\u9a8c\u5c06\u7ee7\u7eed\u8fdb\u884c\u3002<\/p>\n\u8fd9\u4e24\u6761\u6d88\u606f\u5bf9\u4e8e\u8f89\u745e\u7684\u957f\u671f\u6295\u8d44\u8005\u6765\u8bf4\u5f71\u54cd\u4e0d\u5927\u3002\u4e0d\u8fc7\uff0c\u4e0b\u9762\u8fd9\u4e00\u4e2a\u7ea2\u706f\u548c\u4e00\u4e2a\u7eff\u706f\u5e94\u8be5\u5f15\u8d77\u6295\u8d44\u8005\u7684\u8db3\u591f\u91cd\u89c6\u3002<\/p>\n
\u7eff\u706f\uff1a\u8f89\u745e\u5f3a\u5927\u7684\u7814\u53d1\u7ba1\u7ebf<\/h2>\n
\u8fc7\u53bb\u4e24\u4e2a\u6708\uff0c\u8f89\u745e\u65a9\u83b74\u4e2a\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7ba1\u5c40\uff08FDA\uff09\u7684\u836f\u54c1\u6279\u51c6\uff0c\u540c\u65f6\u8be5\u516c\u53f8\u7684\u4e59\u578b\u8840\u53cb\u75c5\u7597\u6cd5fidanacogene elaparvovec\u7684\u751f\u7269\u5236\u5242\u8bb8\u53ef\u7533\u8bf7\uff08BLA\uff09\u5df2\u88abFDA\u63a5\u53d7\uff0cPDUFA\u65e5\u671f\u5b9a\u4e3a2024\u5e74\u4e8c\u5b63\u5ea6\u3002<\/p>\n
\u8f89\u745e\u62e5\u6709101\u4e2a\u5728\u7814\u9879\u76ee\uff0c\u5176\u4e2d38\u5904\u4e8e\u4e09\u671f\u8bd5\u9a8c\u9636\u6bb5\uff0c28\u4e2a\u5904\u4e8e\u4e8c\u671f\u8bd5\u9a8c\u9636\u6bb5\u3002\u8be5\u516c\u53f85\u670831\u65e5\u83b7\u6279\u7684\u547c\u5438\u9053\u5408\u80de\u75c5\u6bd2\uff08RSV\uff09\u75ab\u82d7Abrysvo\u53ef\u4ee5\u9884\u9632\u5e74\u6ee160\u5c81\u7684RSV\u6210\u4eba\u60a3\u8005\u7684\u4e0b\u547c\u5438\u9053\u75be\u75c5\u3002\u5206\u6790\u5e08\u9884\u8ba1\u8fd9\u6b3eRSV\u75ab\u82d7\u6bcf\u5e74\u7684\u5e02\u573a\u4ef7\u503c\u4e3a100\u4ebf\u7f8e\u5143\u3002<\/p>\n
\u6b64\u5916\uff0c3\u6708\u83b7\u6279\u7684\u504f\u5934\u75db\u7597\u6cd5Zavzpret\u9884\u8ba1\u5c06\u57287\u6708\u4e0a\u5e02\uff0c\u5e76\u4e14\u5b83\u8fd8\u662f\u5168\u7403\u9996\u6b3e\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd\uff08CGRP\uff09\u53d7\u4f53\u62ee\u6297\u5242\u9f3b\u8154\u55b7\u96fe\u5242\u3002\u7f8e\u56fd\u504f\u5934\u75db\u57fa\u91d1\u4f1a\u7684\u6570\u636e\u663e\u793a\uff0c\u5168\u7403\u5927\u7ea6\u6bcf7\u4e2a\u4eba\u5f53\u4e2d\u5c31\u67091\u4eba\u60a3\u6709\u504f\u5934\u75db\u3002<\/p>\n
\u7ea2\u706f\uff1a\u76c8\u5229\u9884\u671f\u4e0b\u4fee<\/h2>\n
\u7531\u4e8e\u65b0\u51a0\u75ab\u82d7Comirnaty\u548c\u65b0\u51a0\u836f\u7269Paxlovid\u7684\u9500\u552e\u989d\u4e0b\u6ed1\uff0c\u516c\u53f8\u4e00\u5b63\u5ea6\u6536\u5165\u4e0b\u6ed1\uff0c\u5e76\u4e14\u4eca\u5e74\u5269\u4f59\u65f6\u95f4\u91cc\u5927\u6982\u7387\u5c06\u5ef6\u7eed\u8fd9\u4e00\u8d8b\u52bf\u3002\u5177\u4f53\u6765\u8bf4\uff0c\u6536\u5165\u548c\u6bcf\u80a1\u6536\u76ca\u5747\u540c\u6bd4\u4e0b\u964d29%\u81f3183\u4ebf\u7f8e\u5143\u548c0.97\u7f8e\u5143\uff0c\u5e74\u5ea6\u6536\u5165\u9884\u8ba1\u4e0b\u964d29%-33%\u81f3670-710\u4ebf\u7f8e\u5143\u3002\u4eca\u5e74\u4ee5\u6765\uff0c\u8f89\u745e\u7684\u80a1\u4ef7\u4e0b\u8dcc\u8d85\u8fc728%\u3002<\/p>\n
\u503c\u5f97\u6b23\u6170\u7684\u662f\uff0c\u8f89\u745e\u4eca\u5e74\u5c06\u80a1\u606f\u4e0a\u8c03\u81f3\u6bcf\u80a10.41\u7f8e\u5143\uff0c\u80a1\u606f\u7387\u7ea6\u4e3a4.5%\uff0c\u9ad8\u4e8e\u5e73\u5747\u6c34\u5e73\u3002\u6b64\u5916\uff0c\u8be5\u516c\u53f8\u8fde\u7eed14\u5e74\u4e0a\u8c03\u80a1\u606f\uff0c\u800c\u4e14\u6d3e\u606f\u738734%\uff0c\u6d3e\u606f\u5b89\u5168\u6027\u9ad8\u3002\u4e0d\u8fc7\uff0c\u5982\u679c\u51fa\u73b0\u7ecf\u6d4e\u8870\u9000\uff0c\u8be5\u516c\u53f8\u4e5f\u6709\u53ef\u80fd\u50cf2009\u5e74\u5927\u8427\u6761\u671f\u95f4\u4e00\u6837\u524a\u51cf\u80a1\u606f\u3002<\/p>\n
\u8f89\u745e\u957f\u671f\u9884\u671f\u4e0b\u4fee\u7684\u53e6\u4e00\u4e2a\u53ef\u80fd\u7684\u7406\u7531\u662f\u4e13\u5229\u60ac\u5d16\u30022030\u5e74\u4e4b\u524d\uff0c\u8be5\u516c\u53f8\u7684\u90e8\u5206\u7545\u9500\u836f\uff0c\u6bd4\u5982\u8bf4\u4e73\u817a\u764c\u7597\u6cd5Ibrance\uff082027\u5e74\uff09\uff0c\u5fc3\u808c\u75c7\u836f\u7269Vyndaquel\/Vyndamax\uff082028\u5e74\uff09\uff0c\u7c7b\u98ce\u6e7f\u6027\u5173\u8282\u708e\u836f\u7269Xeljanz\uff082025\u5e74\uff09\u4ee5\u53ca\u6297\u51dd\u836fEliquis\uff082026\u5e74\uff09\u7684\u4e13\u5229\u90fd\u5c06\u5230\u671f\u3002\u6263\u9664\u65b0\u51a0\u836f\u7269\uff0c\u8fd94\u79cd\u836f\u7269\u5360\u8be5\u516c\u53f82022\u5e74\u6536\u5165\u768436.3%\u3002<\/p>\n
\u8f89\u745e\u4f9d\u7136\u662f\u4e00\u53ea\u597d\u80a1\u7968<\/h2>\n
\u867d\u7136\u8d22\u62a5\u662f\u4e00\u4e2a\u98ce\u9669\u70b9\uff0c\u4f46\u8f89\u745e\u5f3a\u5927\u7684\u7814\u53d1\u7ba1\u7ebf\u662f\u6295\u8d44\u8005\u7ee7\u7eed\u6301\u80a1\u7684\u7406\u7531\u3002\u6b64\u5916\uff0c\u8be5\u80a1\u76ee\u524d\u5e02\u76c8\u7387\u4ec5\u67097\uff0c\u4f30\u503c\u6c34\u5e73\u4e5f\u4f4e\u3002\u6700\u540e\uff0c\u8be5\u516c\u53f8\u53bb\u5e74\u6536\u5165\u8fbe1000\u4ebf\u7f8e\u5143\uff0c\u540c\u65f6\u4e3a\u4e86\u63d0\u5347\u6536\u5165\u4e0d\u60dc\u6295\u5165\u91cd\u91d1\uff0c\u6bd4\u5982\u8bf43\u6708\u4e0eSeagen\u7b7e\u7f72430\u4ebf\u7f8e\u5143\u7684\u6536\u8d2d\u534f\u8bae\u3002\u968f\u7740\u65b0\u4ea7\u54c1\u7684\u4e0d\u65ad\u4e0a\u5e02\uff0c\u8f89\u745e\u5c06\u8d8a\u6765\u8d8a\u5f3a\u5927\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u8f89\u745e\u957f\u671f\u6f5c\u529b\u5927\uff0c\u4f46\u5f53\u4e0b\u6709\u9690\u5fe7 \u8f89\u745e\u5236\u836fPfizer\uff08NYSE:PFE\uff09\u7684\u80a1\u4ef7\u6700\u8fd1\u51fa\u73b0\u4e0b\u8dcc\uff0c\u6b64\u524d\u8be5\u516c\u53f8\u5ba3\u5e03\u7ec8\u6b62\u4e00 […]<\/p>\n","protected":false},"author":27,"featured_media":465725,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1521,430],"tags":[455,766,1859,2137],"class_list":["post-465724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1521","category-trends-strategies-zh-hans","tag-455","tag-766","tag-1859","tag-2137","sectors-life-science-zh-hans","locations-us-zh-hans","exchange-nyse-zh-hans"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/465724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=465724"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/465724\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media\/465725"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=465724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=465724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=465724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}